ClinicalTrials.gg
RecruitingNCT05257590Updated Apr 13, 2026

CVM-1118 in Combination With Nivolumab for Unresectable Advanced Hepatocellular Carcinoma

A Phase 2 interventional study of Nivolumab Injection [Opdivo] and CVM-1118 in Hepatocellular Carcinoma and Advanced Cancer, sponsored by TaiRx, Inc.. Recruiting at 5 sites in Taiwan. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-13.

Sponsored by TaiRx, Inc. · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started May 2022; still recruiting 4 years 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
95
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 273 studies in Carcinoma, Hepatocellular with a site in Taiwan — 46 open to participants now, 69 under way, 11 of them phase 3. Carcinoma, Hepatocellular · Taiwan.

Planned enrollment
113th of 224
95 · median 98
Started
2022
with 13 others
Phase 2
70 of 273
14 open now
Primary completion
2026-12
later than 30 of 68 live
Registered
215th of 273
by date

Among the 273 studies in Carcinoma, Hepatocellular with a site in Taiwan, this one is the 113th largest by planned enrollment of the 224 interventional ones that give a count, is one of 14 that started in 2022, is one of 70 in phase 2, reaches primary completion later than 30 of the 68 other live ones, and was the 215th registered.

Carcinoma, Hepatocellular

3,650 studies on the registry are indexed under Carcinoma, Hepatocellular; 1,062 are open to participants now.

Browse Carcinoma, Hepatocellular studies →

Open to participants now

46 of the 273 studies in Carcinoma, Hepatocellular with a site in Taiwan are open now. Recruiting first, the newest first:

41 more — sign in →

All 46 open studies →

A study can be open while its sites in Taiwan have not opened yet or have stopped. Only those recruiting at a site in Taiwan →

Who these studies take

Of the 737 Carcinoma, Hepatocellular studies recruiting now, 382 (52%) set no upper age limit and 249 (34%) stop at 75 or younger; 31 take children under 18; 31 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 273 studies in Carcinoma, Hepatocellular with a site in Taiwan, or all of them as a file.
02

Study summary

CVM-1118 is a new small molecule chemical entity being developed as a potential anti-cancer therapeutic by TaiRx, Inc. CVM-1118 is a potent anti-cancer agent in numerous human cancer cell lines. The safety of administrating CVM-1118 on human has been evaluated from the phase 1 study. The objective of the phase 2 study is to further investigate the efficacy of CVM-1118 with nivolumab for subjects with unresectable advanced hepatoma.

Read the detailed description

Nivolumab, a human IgG4 kappa monoclonal antibody acts as a checkpoint inhibitor, blocking the interaction between PD-1 and its ligands (PD-L1 and PD-L2 ) and therefore preventing the activation of T cells from attacking the cancer. Nivolumab is currently approved for several cancer types.

To meet the medical need, TaiRx, Inc. develops a new small molecule drug, CVM-1118 can promote apoptosis and delay proliferation. Moreover, CVM-1118 targets the formation of vasculogenic mimicry (VM). VM has been associated with tumor metastasis and poor clinical outcomes. VM is reported to be particularly active in tumor under hypoxia state when patients are treated with the potent vascular endothelial growth factor (VEGF) inhibitor like sorafenib or bevacizumab. Hence, the ability of inhibiting the VM network makes CVM-1118 a potential good combination drug with Nivolumab in advanced diseases such as hepatoma where Nivolumab alone has shown activity.

The safety profile of CVM-1118 dosing has been established in the phase 1 study. The analysis of metabolism pathways further showed that the potential drug-drug interactions of CVM-1118 and Nivolumab are very low.

Based on the mechanism of actions and the safety analysis of nivolumab and CVM-1118, the design of phase 2 trial with the combination therapy might have great potential for the patients with unresectable advanced HCC.

03

Conditions studied

  • Hepatocellular Carcinoma
  • Advanced Cancer

Keywords

  • Oncology
  • Hepatocellular Carcinoma (HCC)
  • Nivolumab
  • Hepatoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18+ (20+ for subjects in Taiwan)
  • Diagnosis of hepatocellular carcinoma

    • or cytologically-confirmed or clinically diagnosed in accordance with American Association for the Study of Liver Diseases (AASLD) criteria (i.e., radiologic imaging with cross-sectional multiphasic contrast CT or MRI showing a ≥ 1 cm liver lesion)
  • Subjects with advanced-stage, unresectable hepatocellular carcinoma that is not appropriate for potentially curable therapy who have progressed from, been intolerant of prior systemic anti-cancer therapies (e.g., sorafenib, lenvatinib, atezolizumab in combination with bevacizumab).
  • Barcelona Clinic Liver Cancer (BCLC) stage B not appropriate for or with disease progression after local regional therapy, or BCLC stage C
  • liver function class A
  • (per )
  • performance status of 0 to 1
  • Adequate laboratory parameters including:

    • and ALT ≤ 3.0 x (≤ 5.0 x ULN if due to liver involvement)
    • Total serum ≤ 2.0 x ULN (≤ 3.0 x ULN for subjects with documented Gilbert's syndrome)
    • ≥1500/µL
    • ≥ 90,000/µL
    • HGB ≥ 9.0 g/dL
    • Serum of ≥ 50 mL/min based on Cockcroft-Gault formula
    • Serum albumin ≥ 2.8 gm/dL
    • ≤ 2.3
    • PT/aPTT ≤ 1.2 x ULN
  • ≤ 480 msec
  • Subjects are eligible to enroll if they have -, or -HCC, defined as follows:

    • Chronic HBV infection as evidenced by detectable HBV DNA or HBsAg. Subjects with chronic HBV infection must be on antiviral therapy and have HBV DNA \<500 IU/mL. If not on an antiviral therapy at screening, then subjects must be willing to start the antiviral therapy at the time of consent.
    • Active or resolved HCV infection as evidenced by detectable HCV RNA or antibody.

Exclusion criteria

Exclusion Criteria:

  • HCC with portal vein invasion at the main portal branch (Vp4)
  • Known history of esophageal varices or gastrointestinal bleeding within the past 3 months
  • Prior immunotherapy for hepatoma
  • ≤ 7 days from prior limited field palliative irradiation therapy and C1D1
  • ≤ 28 days from prior irradiation therapy and C1D1
  • ≤ 14 days (or 5 half-lives) from prior systemic anticancer therapy and C1D1
  • ≤ 28 days from local regional therapy (e.g., trans-arterial embolization, radiofrequency ablation) and C1D1
  • Presence of other active cancer(s) likely to require treatment in the next two (2) years or likely to impact the assessment of any study endpoints
  • Active bacterial or fungal infection(s) requiring systemic therapy within 7 days prior to C1D1
  • Known
  • Known history of infection
  • Females who are currently pregnant or breast-feeding
  • Known gastrointestinal disease that may significantly alter the absorption of oral medications
  • Psychiatric illness or social situation that would interfere with compliance with study requirements
  • History of cardiovascular abnormalities
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

iRECIST and mRECIST

Versions of RECIST adapted to particular cases. iRECIST is for immunotherapy, where a tumor can look bigger for a while before it shrinks, so growth has to be confirmed on a later scan. mRECIST usually means the version for liver cancer (hepatocellular carcinoma), which measures only the part of a tumor that still has a blood supply.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
95 participants (estimated)

Study arms

  • Experimental
    Nivolumab + CVM-1118

    1 Cycle = 28 days Nivolumab, 240 mg, IV, Q2 weeks with an option for 480 mg, IV, Q4 weeks starting from Cycle 3 if judged to be reasonable by the investigator based on the safety and tolerability. CVM-1118, 200 mg, PO, BID with an option to increase the starting dose to 300 mg, PO, BID for the subsequent subjects following assessment of safety data from the initial 10 subjects. Escalation of the starting dose will be dependent on the absence of Dose Limiting Toxicity in at least 7 of the initial 10 subjects treated at 200 mg, PO, BID. Individual subjects receiving a starting dose of 200 mg, PO, BID and who tolerate the initial 2 cycles with no more than Grade 2 related toxicity, will have the option of increasing their dose of CVM-1118 to 300 mg, PO, BID (600 mg total daily dose) starting with cycle 3 Tolerable dose of Nivolumab and CVM-1118 will be administered continuously for a 28-day cycle until progressive disease, unacceptable toxicity, or consent withdrawal.

    Drug: Nivolumab Injection [Opdivo] · Drug: CVM-1118

Interventions

  • Nivolumab will be administered at 240 mg, IV, Q2 weeks with an option for 480 mg, IV, Q4 weeks starting with Cycle 3 if judged to be reasonable by the investigator based on the safety and tolerability.

    Also known as: Nivolumab

  • CVM-1118 will be administered 200 mg, PO, BID with an option to increase the starting dose to 300 mg, PO, BID for the subsequent subjects following assessment of safety data from the initial 10 subjects.

    Also known as: TRX-818

06

What researchers measure

Primary outcomes

  1. Objective Response Rate (ORR)_mRECIST

    Assessment by modified RECIST criteria

    Time frame: 24 weeks after the last subject starts CVM-1118

Secondary outcomes

  1. Objective Response Rate (ORR)_RECIST v1.1

    Assessment by RECIST v1.1 criteria

    Time frame: 24 weeks after the last subject starts CVM-1118

  2. Duration of response (DoR)

    Duration of response (DoR) is defined as time from the first documentation of response to the time of progression

    Time frame: 24 weeks after the last subject starts CVM-1118 up to 1 year after the last-dose

  3. Progression free survival (PFS)

    Progression free survival (PFS) is defined as time from the first dose of study drug to the time of progression or death

    Time frame: 24 weeks after the last subject starts CVM-1118 up to 1 year after the last-dose

  4. Overall survival (OS)

    Overall survival (OS) is defined as time from first dose of study drug to death

    Time frame: 24 weeks after the last subject starts CVM-1118 and up to 1 year after the last-dose

  5. Time to progression (TTP)

    Time to progression (TTP) is defined as the time from the first dose of study drug to the time of progression

    Time frame: 24 weeks after the last subject starts CVM-1118 up to 1 year after the last-dose

  6. Disease control rate (DCR)

    Disease control rate (DCR) is defined as the sum of complete response (CR), partial response (PR), and stable disease rate (SD)

    Time frame: 24 weeks after the last subject starts CVM-1118 and up to 1 year after the last-dose

  7. Rate of Adverse event (AE) and Serious Adverse Event (SAE)

    Rate of Adverse event (AE) and Serious Adverse Event (SAE) are assessed using Common Terminology Criteria for Adverse Events v.5 (CTCAE) criteria

    Time frame: Starting form the first dose of combination treatment until 28 days (for all AE/SAE) and 90 days (for immune related AE/SAE) following the last dose of treatment by CTCAE v5.

  8. Number of Participants With Abnormal Vital Sign

    Values with CTCAE v5 Grade ≧ 3 will be identified with flags. A final outcome result with the number of participants with abnormal vital sign would be provided. Normal ranges will also be provided.

    Time frame: Starting form the first dose of combination treatment until 28 days (for all AE/SAE) and 90 days (for immune related AE/SAE) following the last dose of treatment

  9. Number of Participants With Abnormal Vital Sign_Assessed the baseline and out-of-range vital signs_ blood pressure (both systolic and diastolic blood pressure) by CTCAE v5

    Both systolic and diastolic blood pressure will be measured. Values with CTCAE v5 Grade ≧ 3 will be identified with flags. A final outcome result with the number of participants with abnormal vital sign would be provided. Normal ranges will also be provided.

    Time frame: Starting form the first dose of combination treatment until 28 days (for all AE/SAE) and 90 days (for immune related AE/SAE) following the last dose of treatment

  10. Number of Participants With Abnormal Vital Sign_Assessed the baseline and out-of-range vital signs_ Heart rate by CTCAE v5

    Values with CTCAE v5 Grade ≧ 3 will be identified with flags. A final outcome result with the number of participants with abnormal vital sign would be provided. Normal ranges will also be provided.

    Time frame: Starting form the first dose of combination treatment until 28 days (for all AE/SAE) and 90 days (for immune related AE/SAE) following the last dose of treatment

  11. Number of Participants With Abnormal Vital Sign_Assessed the baseline and out-of-range vital signs_ respiratory rate by CTCAE v5

    Values with CTCAE v5 Grade ≧ 3 will be identified with flags. A final outcome result with the number of participants with abnormal vital sign would be provided. Normal ranges will also be provided.

    Time frame: Starting form the first dose of combination treatment until 28 days (for all AE/SAE) and 90 days (for immune related AE/SAE) following the last dose of treatment

  12. Number of Participants With Abnormal baseline and out-of range Hematology Count by CTCAE v5

    Values with CTCAE v5 Grade ≧ 3 will be identified with flags. A final outcome result with the number of participants with abnormal laboratory values would be provided. A list of all laboratory normal ranges will also be provided.

    Time frame: Starting form the first dose of combination treatment until 28 days (for all AE/SAE) and 90 days (for immune related AE/SAE) following the last dose of treatment

  13. Number of Participants With Abnormal Laboratory Values_Assessed the baseline and out-of range coagulation test by CTCAE v5

    Values with CTCAE v5 Grade ≧ 3 will be identified with flags. A final outcome result with the number of participants with abnormal laboratory values would be provided. A list of all laboratory normal ranges will also be provided.

    Time frame: Starting form the first dose of combination treatment until 28 days (for all AE/SAE) and 90 days (for immune related AE/SAE) following the last dose of treatment

  14. Number of Participants With Abnormal Laboratory Values_Assessed the baseline and out-of range urinalysis test by CTCAE v5

    Values with CTCAE v5 Grade ≧ 3 will be identified with flags. A final outcome result with the number of participants with abnormal laboratory values would be provided. A list of all laboratory normal ranges will also be provided.

    Time frame: Starting form the first dose of combination treatment until 28 days (for all AE/SAE) and 90 days (for immune related AE/SAE) following the last dose of treatment

  15. Number of patients with abnormalities in electrocardiography (ECG) reporting for PR, QRS, QT, and QTcF intervals

    Values with CTCAE v5 Grade ≧ 3 will be identified with flags. A final outcome result with the number of participants with abnormal laboratory values would be provided. A list of all laboratory normal ranges will also be provided.

    Time frame: Starting form the first dose of combination treatment until 28 days (for all AE/SAE) and 90 days (for immune related AE/SAE) following the last dose of treatment

  16. Maximum Plasma Concentration [Cmax] of CVM-1118 and its metabolite CVM-1125 after CVM-1118 dosing

    Maximum Plasma Concentration \[Cmax\] of CVM-1118 and its metabolite CVM-1125 will be measured to see maximum exposure after CVM-1118 dosing

    Time frame: During Cycle 1 and Cycle 2 (each cycle is 28 days)

  17. Area Under the Curve [AUC] of CVM-1118 and its metabolite CVM-1125 after CVM-1118 dosing

    Area Under the Curve \[AUC\] of CVM-1118 and its metabolite CVM-1125 after CVM-1118 dosing

    Time frame: During Cycle 1 and Cycle 2 (each cycle is 28 days)

  18. Pharmacodynamics analysis for the relationship of Cmax and ORR

    Relationship between Cmax and ORR will be evaluated

    Time frame: During Cycle 1 and Cycle 2 (each cycle is 28 days)

  19. Pharmacodynamics analysis for the relationship of AUC and ORR

    Relationship between AUC and ORR will be evaluated

    Time frame: During Cycle 1 and Cycle 2 (each cycle is 28 days)

  20. Pharmacodynamics analysis for the relationship of Cmax and AE

    Relationship between Cmax and AE will be evaluated

    Time frame: During Cycle 1 and Cycle 2 (each cycle is 28 days)

  21. Pharmacodynamics analysis for the relationship of AUC and AE

    Relationship between AUC and AE will be evaluated

    Time frame: During Cycle 1 and Cycle 2 (each cycle is 28 days)

07

Study locations

5 of 5 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2022 (actual). Primary completion is estimated for Dec 2026, 55 months after the start.

Of 80 industry-sponsored phase 2 interventional studies under Carcinoma, Hepatocellular, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 50. This study's planned 55 months is above that.

Counting every sponsor, half of 428 studies reached it within 43 months; a quarter within 30 and three quarters within 71.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 8, 2022
First posted
Feb 25, 2022
StartActual
May 23, 2022
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2026
Last update
Apr 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05257590
Lead sponsor
TaiRx, Inc.
Responsible party
Sponsor
First posted
Feb 25, 2022
Start date
May 23, 2022
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Apr 13, 2026

Study contacts

Yen-Ling Chen, PhD
Contact
yenlingchen@trx.com.tw
886-2-2653-5007 ext. 113
Pei-Jer Chen, MD/PhD
principal investigator · National Taiwan University Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Foslinanib

Start the discussion